The company seeks to develop a suite of intraoperative diagnostic tools designed to provide real-time assessment and protection of vertebral endplate integrity.
The UK-based company will focus on preparation for U.S. regulatory clearance and commercial launch, strategic partnering, business development initiatives, etc.
Findings support use of the non-invasive platform for advanced infection care by enhancing antibiotic effectiveness against implant-associated biofilms.